Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, was among the thousands of FDA employees who lost their jobs due to a restructuring initiative by the Department of Health and Human Services aimed at saving $1.8 billion annually. Analysts warn that Marks’ departure could affect the regulatory guidance for the development of biologic medicines, particularly in the area of cell and gene therapies.
HSCC CWG urges halting NPRM, calls for joint cybersecurity policy reform to boost healthcare resilience
The Cybersecurity Working Group (CWG) within the U.S. Healthcare and Public Health Sector Coordinating Council (HSCC) has called on the country’s federal administration to work
